RxDoctor Payments DataLook up a doctor →

Casey Jeffreys, MD

Neurology · Raleigh, NCNPI 1619395092

Payments from drug & device makers

$2,166,703in general payments, 2019–2025

Across 933 payments — averaging $2322.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$2.1M
  • EMD Serono, Inc.$27K
  • Biogen$15K
  • Genentech USA, Inc.$14K
  • Sanofi$6K
  • TG Therapeutics, Inc.$2K
  • plus $10K from 48 others

What the payments were for

  • Consulting fees$42,90552%
  • Speaking & faculty fees$16,62520%
  • Travel & lodging$3,3274%
  • Food & beverage$18,99523%
  • Education$3300%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,166,703 in reported general payments places this provider in the 95th percentile of 566 neurology providers in North Carolina.

See all neurology providers in North Carolina

Medicare billing

Part B allowed, 2024
$1,626,663
Medicare patients
427
Services billed
51,361

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Kesimpta PenOfatumumab89$845,238
OcrevusOcrelizumab19$783,679
Avonex (4 Pack)Interferon Beta-1a66$589,721
RebifInterferon Beta-1a/Albumin37$416,534
Avonex Pen (4 Pack)Interferon Beta-1a25$340,167
VumerityDiroximel Fumarate38$325,215
MayzentSiponimod30$297,095
GilenyaFingolimod Hcl24$291,017
Rebif RebidoseInterferon Beta-1a/Albumin14$147,486
TysabriNatalizumab13$109,856
Dalfampridine ErDalfampridine88$51,290
Nurtec OdtRimegepant Sulfate33$36,649
FingolimodFingolimod Hcl36$19,506
Emgality PenGalcanezumab-Gnlm27$18,487
UbrelvyUbrogepant14$15,009

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BiogenAvonex (4 Pack), Vumerity, Tysabri$15,343$1,024,792117 claims
Genentech, Inc.Ocrevus$120$783,67919 claims
NovartisMayzent, Gilenya$2,092,290$588,11254 claims
EMD Serono, Inc.Rebif$26,840$416,53437 claims
PfizerNurtec Odt, Dilantin$470$41,71450 claims
AbbVieUbrelvy, Linzess$808$22,65727 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 566 neurology providers in North Carolina.

Other neurology in Raleigh

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →